Graft vs Host Disease (GVHD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032
Graft vs Host Disease (GVHD) is a pattern of transplant rejection in which donor immune cells mount an immune response against host tissues. GVHD occurs when the donor’s T cells (the graft) view the patient’s healthy cells (the host) as foreign and attack and damage them. Graft-versus-host disease can be mild, moderate or severe. In some cases, it can be life-threatening.
- The incidence of chronic GVHD ranges from 6% to 80%. GVHD is considered one of the main causes of morbidity and mortality after HCT; more than 10% of patients will die from this complication.
Thelansis’s “Graft vs Host Disease (GVHD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Graft vs Host Disease (GVHD) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Graft vs Host Disease (GVHD) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Graft vs Host Disease (GVHD) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment